Global Esophageal Disorders Treatment Market

Esophageal Disorders Treatment Comprehensive Study by Application (Hospital Pharmacies, Retail Pharmacy, Drug Stores, Online), Drug Type (Antacids, H2 Blockers, Proton Pump Inhibitors, Prokinetics, Others), Indication (GERD, Eosinophilic Esophagitis, Dysphagia, Achalasia, Esophageal Diverticula, Hiatus Hernia, Others) Players and Region - Global Market Outlook to 2026

Esophageal Disorders Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Esophageal Disorders Treatment Market?

Infectious diseases of the esophagus are infections caused by bacteria, fungi, or viruses in the esophagus. The most common symptoms of infectious diseases of the esophagus are fever, heartburn, difficulty swallowing, swollen glands, painful swallowing. There is an increasing demand for the treatment of infectious diseases of the esophagus due to increasing cases of diseases such as GERD etc. In addition, market participants are trying to expand the therapeutic use of drugs for the treatment of infectious diseases of the esophagus, creating more possibilities and leeway for that Growth in Infectious Market will be created for the treatment of esophageal diseases in the forecast years. The growing number of patients with esophageal infectious diseases is the main driver of the growth of the market for the treatment of esophageal infectious diseases. The increasing use of drugs to treat esophageal infectious diseases such as GERD and esophageal dysmotility is expected to further fuel the growth of the esophageal infectious disease treatment market. The increasing FDA approvals for drugs used to treat esophageal infections are expected to further support the growth of the esophageal treatment market. Intensive research and development activities to expand the therapeutic uses of drugs for the treatment of diseases of the esophagus are expected to continue to support the growth of the market for the treatment of diseases of the esophagus in the forecast years. The presence of a large number of manufacturers of treatments for infectious diseases of the esophagus further promotes the growth of the market for the treatment of infectious diseases of the esophagus. However, there are several adverse effects associated with the treatment of infectious diseases of the esophagus, which in turn is hindering the growth of the market for the treatment of infectious diseases of the esophagus.

The market study is being classified, by Application (Hospital Pharmacies, Retail Pharmacy, Drug Stores and Online) and major geographies with country level break-up.

Pfizer (United States), Bristol-Myers Squibb Company (United States), Perrigo Company plc (Ireland), AstraZeneca plc (United Kingdom), GlaxoSmithKline Plc (United Kingdom), Johnson & Johnson (United States), Teva Pharmaceuticals (Israel), Medtronic plc (Ireland) and Torax Medical (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Esophageal Disorders Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Esophageal Disorders Treatment market by Type, Application and Region.

On the basis of geography, the market of Esophageal Disorders Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Awareness of People towards the Early Treatment of Infectious Esophageal Disorders
  • Growing lifestyle changes leading to obesity
  • Increasing Consumption of Alcohol

Market Trend
  • The Higher Disposable Income of the People
  • The Increasing Prevalence of Esophageal Disorders

Restraints
  • The Lack of Awareness
  • Several Adverse Effects Associated With the Treatment

Opportunities
  • The Higher Adoption of Infectious Esophageal Disorders Treatment Drugs In Developing Regions
  • Intensive Research and Development Activities to Expand the Therapeutic Application of Infectious Esophageal Disorders Treatment Drugs

Challenges
  • Least Availability of Infectious Esophageal Disorder Treatment in Under Developed Regions





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Esophageal Disorders Treatment, Venture Capitalists and Private Equity Firms and End-Use Industry

Report Objectives / Segmentation Covered

By Application
  • Hospital Pharmacies
  • Retail Pharmacy
  • Drug Stores
  • Online
By Drug Type
  • Antacids
  • H2 Blockers
  • Proton Pump Inhibitors
  • Prokinetics
  • Others

By Indication
  • GERD
  • Eosinophilic Esophagitis
  • Dysphagia
  • Achalasia
  • Esophageal Diverticula
  • Hiatus Hernia
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness of People towards the Early Treatment of Infectious Esophageal Disorders
      • 3.2.2. Growing lifestyle changes leading to obesity
      • 3.2.3. Increasing Consumption of Alcohol
    • 3.3. Market Challenges
      • 3.3.1. Least Availability of Infectious Esophageal Disorder Treatment in Under Developed Regions
    • 3.4. Market Trends
      • 3.4.1. The Higher Disposable Income of the People
      • 3.4.2. The Increasing Prevalence of Esophageal Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Esophageal Disorders Treatment, by Application, Drug Type, Indication and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Esophageal Disorders Treatment (Value)
      • 5.2.1. Global Esophageal Disorders Treatment by: Application (Value)
        • 5.2.1.1. Hospital Pharmacies
        • 5.2.1.2. Retail Pharmacy
        • 5.2.1.3. Drug Stores
        • 5.2.1.4. Online
      • 5.2.2. Global Esophageal Disorders Treatment by: Drug Type (Value)
        • 5.2.2.1. Antacids
        • 5.2.2.2. H2 Blockers
        • 5.2.2.3. Proton Pump Inhibitors
        • 5.2.2.4. Prokinetics
        • 5.2.2.5. Others
      • 5.2.3. Global Esophageal Disorders Treatment by: Indication (Value)
        • 5.2.3.1. GERD
        • 5.2.3.2. Eosinophilic Esophagitis
        • 5.2.3.3. Dysphagia
        • 5.2.3.4. Achalasia
        • 5.2.3.5. Esophageal Diverticula
        • 5.2.3.6. Hiatus Hernia
        • 5.2.3.7. Others
      • 5.2.4. Global Esophageal Disorders Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Esophageal Disorders Treatment (Price)
  • 6. Esophageal Disorders Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Perrigo Company plc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceuticals (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Medtronic plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Torax Medical (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Esophageal Disorders Treatment Sale, by Application, Drug Type, Indication and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Esophageal Disorders Treatment (Value)
      • 7.2.1. Global Esophageal Disorders Treatment by: Application (Value)
        • 7.2.1.1. Hospital Pharmacies
        • 7.2.1.2. Retail Pharmacy
        • 7.2.1.3. Drug Stores
        • 7.2.1.4. Online
      • 7.2.2. Global Esophageal Disorders Treatment by: Drug Type (Value)
        • 7.2.2.1. Antacids
        • 7.2.2.2. H2 Blockers
        • 7.2.2.3. Proton Pump Inhibitors
        • 7.2.2.4. Prokinetics
        • 7.2.2.5. Others
      • 7.2.3. Global Esophageal Disorders Treatment by: Indication (Value)
        • 7.2.3.1. GERD
        • 7.2.3.2. Eosinophilic Esophagitis
        • 7.2.3.3. Dysphagia
        • 7.2.3.4. Achalasia
        • 7.2.3.5. Esophageal Diverticula
        • 7.2.3.6. Hiatus Hernia
        • 7.2.3.7. Others
      • 7.2.4. Global Esophageal Disorders Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Esophageal Disorders Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Esophageal Disorders Treatment: by Application(USD Million)
  • Table 2. Esophageal Disorders Treatment Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 3. Esophageal Disorders Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 4. Esophageal Disorders Treatment Drug Stores , by Region USD Million (2015-2020)
  • Table 5. Esophageal Disorders Treatment Online , by Region USD Million (2015-2020)
  • Table 6. Esophageal Disorders Treatment: by Drug Type(USD Million)
  • Table 7. Esophageal Disorders Treatment Antacids , by Region USD Million (2015-2020)
  • Table 8. Esophageal Disorders Treatment H2 Blockers , by Region USD Million (2015-2020)
  • Table 9. Esophageal Disorders Treatment Proton Pump Inhibitors , by Region USD Million (2015-2020)
  • Table 10. Esophageal Disorders Treatment Prokinetics , by Region USD Million (2015-2020)
  • Table 11. Esophageal Disorders Treatment Others , by Region USD Million (2015-2020)
  • Table 12. Esophageal Disorders Treatment: by Indication(USD Million)
  • Table 13. Esophageal Disorders Treatment GERD , by Region USD Million (2015-2020)
  • Table 14. Esophageal Disorders Treatment Eosinophilic Esophagitis , by Region USD Million (2015-2020)
  • Table 15. Esophageal Disorders Treatment Dysphagia , by Region USD Million (2015-2020)
  • Table 16. Esophageal Disorders Treatment Achalasia , by Region USD Million (2015-2020)
  • Table 17. Esophageal Disorders Treatment Esophageal Diverticula , by Region USD Million (2015-2020)
  • Table 18. Esophageal Disorders Treatment Hiatus Hernia , by Region USD Million (2015-2020)
  • Table 19. Esophageal Disorders Treatment Others , by Region USD Million (2015-2020)
  • Table 20. South America Esophageal Disorders Treatment, by Country USD Million (2015-2020)
  • Table 21. South America Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 22. South America Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 23. South America Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 24. Brazil Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 25. Brazil Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 26. Brazil Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 27. Argentina Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 28. Argentina Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 29. Argentina Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 30. Rest of South America Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 31. Rest of South America Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 32. Rest of South America Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 33. Asia Pacific Esophageal Disorders Treatment, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 36. Asia Pacific Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 37. China Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 38. China Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 39. China Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 40. Japan Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 41. Japan Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 42. Japan Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 43. India Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 44. India Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 45. India Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 46. South Korea Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 47. South Korea Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 48. South Korea Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 49. Taiwan Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 50. Taiwan Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 51. Taiwan Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 52. Australia Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 53. Australia Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 54. Australia Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 58. Europe Esophageal Disorders Treatment, by Country USD Million (2015-2020)
  • Table 59. Europe Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 60. Europe Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 61. Europe Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 62. Germany Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 63. Germany Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 64. Germany Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 65. France Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 66. France Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 67. France Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 68. Italy Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 69. Italy Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 70. Italy Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 71. United Kingdom Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 72. United Kingdom Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 73. United Kingdom Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 74. Netherlands Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 75. Netherlands Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 76. Netherlands Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 77. Rest of Europe Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 78. Rest of Europe Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 79. Rest of Europe Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 80. MEA Esophageal Disorders Treatment, by Country USD Million (2015-2020)
  • Table 81. MEA Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 82. MEA Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 83. MEA Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 84. Middle East Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 85. Middle East Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 86. Middle East Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 87. Africa Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 88. Africa Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 89. Africa Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 90. North America Esophageal Disorders Treatment, by Country USD Million (2015-2020)
  • Table 91. North America Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 92. North America Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 93. North America Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 94. United States Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 95. United States Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 96. United States Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 97. Canada Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 98. Canada Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 99. Canada Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 100. Mexico Esophageal Disorders Treatment, by Application USD Million (2015-2020)
  • Table 101. Mexico Esophageal Disorders Treatment, by Drug Type USD Million (2015-2020)
  • Table 102. Mexico Esophageal Disorders Treatment, by Indication USD Million (2015-2020)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Esophageal Disorders Treatment: by Application(USD Million)
  • Table 113. Esophageal Disorders Treatment Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 114. Esophageal Disorders Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 115. Esophageal Disorders Treatment Drug Stores , by Region USD Million (2021-2026)
  • Table 116. Esophageal Disorders Treatment Online , by Region USD Million (2021-2026)
  • Table 117. Esophageal Disorders Treatment: by Drug Type(USD Million)
  • Table 118. Esophageal Disorders Treatment Antacids , by Region USD Million (2021-2026)
  • Table 119. Esophageal Disorders Treatment H2 Blockers , by Region USD Million (2021-2026)
  • Table 120. Esophageal Disorders Treatment Proton Pump Inhibitors , by Region USD Million (2021-2026)
  • Table 121. Esophageal Disorders Treatment Prokinetics , by Region USD Million (2021-2026)
  • Table 122. Esophageal Disorders Treatment Others , by Region USD Million (2021-2026)
  • Table 123. Esophageal Disorders Treatment: by Indication(USD Million)
  • Table 124. Esophageal Disorders Treatment GERD , by Region USD Million (2021-2026)
  • Table 125. Esophageal Disorders Treatment Eosinophilic Esophagitis , by Region USD Million (2021-2026)
  • Table 126. Esophageal Disorders Treatment Dysphagia , by Region USD Million (2021-2026)
  • Table 127. Esophageal Disorders Treatment Achalasia , by Region USD Million (2021-2026)
  • Table 128. Esophageal Disorders Treatment Esophageal Diverticula , by Region USD Million (2021-2026)
  • Table 129. Esophageal Disorders Treatment Hiatus Hernia , by Region USD Million (2021-2026)
  • Table 130. Esophageal Disorders Treatment Others , by Region USD Million (2021-2026)
  • Table 131. South America Esophageal Disorders Treatment, by Country USD Million (2021-2026)
  • Table 132. South America Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 133. South America Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 134. South America Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 135. Brazil Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 136. Brazil Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 137. Brazil Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 138. Argentina Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 139. Argentina Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 140. Argentina Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 141. Rest of South America Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 142. Rest of South America Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 143. Rest of South America Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 144. Asia Pacific Esophageal Disorders Treatment, by Country USD Million (2021-2026)
  • Table 145. Asia Pacific Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 146. Asia Pacific Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 147. Asia Pacific Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 148. China Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 149. China Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 150. China Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 151. Japan Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 152. Japan Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 153. Japan Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 154. India Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 155. India Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 156. India Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 157. South Korea Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 158. South Korea Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 159. South Korea Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 160. Taiwan Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 161. Taiwan Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 162. Taiwan Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 163. Australia Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 164. Australia Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 165. Australia Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 166. Rest of Asia-Pacific Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 168. Rest of Asia-Pacific Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 169. Europe Esophageal Disorders Treatment, by Country USD Million (2021-2026)
  • Table 170. Europe Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 171. Europe Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 172. Europe Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 173. Germany Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 174. Germany Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 175. Germany Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 176. France Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 177. France Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 178. France Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 179. Italy Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 180. Italy Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 181. Italy Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 182. United Kingdom Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 183. United Kingdom Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 184. United Kingdom Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 185. Netherlands Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 186. Netherlands Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 187. Netherlands Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 188. Rest of Europe Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 189. Rest of Europe Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 190. Rest of Europe Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 191. MEA Esophageal Disorders Treatment, by Country USD Million (2021-2026)
  • Table 192. MEA Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 193. MEA Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 194. MEA Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 195. Middle East Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 196. Middle East Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 197. Middle East Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 198. Africa Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 199. Africa Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 200. Africa Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 201. North America Esophageal Disorders Treatment, by Country USD Million (2021-2026)
  • Table 202. North America Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 203. North America Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 204. North America Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 205. United States Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 206. United States Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 207. United States Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 208. Canada Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 209. Canada Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 210. Canada Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 211. Mexico Esophageal Disorders Treatment, by Application USD Million (2021-2026)
  • Table 212. Mexico Esophageal Disorders Treatment, by Drug Type USD Million (2021-2026)
  • Table 213. Mexico Esophageal Disorders Treatment, by Indication USD Million (2021-2026)
  • Table 214. Research Programs/Design for This Report
  • Table 215. Key Data Information from Secondary Sources
  • Table 216. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Esophageal Disorders Treatment: by Application USD Million (2015-2020)
  • Figure 5. Global Esophageal Disorders Treatment: by Drug Type USD Million (2015-2020)
  • Figure 6. Global Esophageal Disorders Treatment: by Indication USD Million (2015-2020)
  • Figure 7. South America Esophageal Disorders Treatment Share (%), by Country
  • Figure 8. Asia Pacific Esophageal Disorders Treatment Share (%), by Country
  • Figure 9. Europe Esophageal Disorders Treatment Share (%), by Country
  • Figure 10. MEA Esophageal Disorders Treatment Share (%), by Country
  • Figure 11. North America Esophageal Disorders Treatment Share (%), by Country
  • Figure 12. Global Esophageal Disorders Treatment share by Players 2020 (%)
  • Figure 13. Global Esophageal Disorders Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Esophageal Disorders Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer (United States) Revenue: by Geography 2020
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 20. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 21. Perrigo Company plc (Ireland) Revenue: by Geography 2020
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 24. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 27. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 28. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 30. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 31. Medtronic plc (Ireland) Revenue: by Geography 2020
  • Figure 32. Torax Medical (United States) Revenue, Net Income and Gross profit
  • Figure 33. Torax Medical (United States) Revenue: by Geography 2020
  • Figure 34. Global Esophageal Disorders Treatment: by Application USD Million (2021-2026)
  • Figure 35. Global Esophageal Disorders Treatment: by Drug Type USD Million (2021-2026)
  • Figure 36. Global Esophageal Disorders Treatment: by Indication USD Million (2021-2026)
  • Figure 37. South America Esophageal Disorders Treatment Share (%), by Country
  • Figure 38. Asia Pacific Esophageal Disorders Treatment Share (%), by Country
  • Figure 39. Europe Esophageal Disorders Treatment Share (%), by Country
  • Figure 40. MEA Esophageal Disorders Treatment Share (%), by Country
  • Figure 41. North America Esophageal Disorders Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Bristol-Myers Squibb Company (United States)
  • Perrigo Company plc (Ireland)
  • AstraZeneca plc (United Kingdom)
  • GlaxoSmithKline Plc (United Kingdom)
  • Johnson & Johnson (United States)
  • Teva Pharmaceuticals (Israel)
  • Medtronic plc (Ireland)
  • Torax Medical (United States)
Select User Access Type

Key Highlights of Report


Apr 2021 200 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Esophageal Disorders Treatment Market Quantitative research analysis
Global Esophageal Disorders Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Awareness of People towards the Early Treatment of Infectious Esophageal Disorders " is seen as one of major growth factors of Esophageal Disorders Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Esophageal Disorders Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Autism Treatment Comprehensive Study by Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), Drugs (SSRIs, Anti-Convulsant, Others), Treatment (Aba, Hyperbaric Oxygen Therapy, Others) ...
$ 3500
Sound Therapy Comprehensive Study by Type (Guided Meditation, Neurologic Music Therapy, Bonny Method, Others), Application (Tinnitus & Hearing, Children & Learning, Emotional & Stress Relief, Brain P...
$ 3650
Rare hematology disorders Comprehensive Study by Type (Rare blood cancers, Platelet based disorders, Plasma disorders, Myeloproliferative disorders, Genetic hematology disorders), Route of Administra...
$ 3650
Astigmatism Treatment Comprehensive Study by Type (Eyeglasses, Contact lens, Orthokeratology, Laser surgeries, LASIK(Laser- Assisted In situ Keratomileusis), LASEK(Laser- Assisted Subepithelial Kerat...
$ 3750
Cutaneous Squamous Cell Carcinoma Comprehensive Study by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Others), Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Ele...
$ 3450
Diverticular Treatment Comprehensive Study by Type (Antibiotics Treatment, Symptomatic Treatment), Application (Diverticulosis, Diverticulitis), Indication (Symptomatic Uncomplicated Diverticular Dis...
$ 3750